Bugs That Can Resist Antibiotics but Not Men: Gender-Specific Differences in Notified Infections and Colonisations in Germany, 2010–2019

Data from surveillance networks show that men have a higher incidence rate of infections with anti-microbial-resistant (AMR) pathogens than women. We systematically analysed data of infections and colonisations with AMR pathogens under mandatory surveillance in Germany to quantify gender-specific differences. We calculated incidence-rates (IR) per 100,000 person–years for invasive infections with Methicillin-resistant Staphylococcus aureus (MRSA), and for infections or colonisations with carbapenem-non-susceptible Acinetobacter spp. (CRA), and Enterobacterales (CRE), using the entire German population as a denominator. We limited the study periods to years with complete notification data (MRSA: 2010–2019, CRA/CRE: 2017–2019). We used Poisson regression to adjust for gender, age group, federal state, and year of notification. In the study periods, IR for all notifications were 4.2 for MRSA, 0.90 for CRA, and 4.8 for CRE per 100,000 person-–years. The adjusted IR ratio for infections of men compared to women was 2.3 (95% confidence interval [CI]: 2.2–2.3) for MRSA, 2.2 (95%CI: 1.9–2.7) for CRA, and 1.7 (95%CI: 1.6–1.8) for CRE. Men in Germany show about double the risk for infection with AMR pathogens than women. This was also true for colonisations, where data were available. Screening procedures and associated hygiene measures may profit from a gender-stratified approach.Peer Reviewe

Completeness of tuberculosis case notifications in Germany in 2013–2017: first results of an inventory study

Background Evaluating the completeness of tuberculosis (TB) notification data is important for monitoring of TB surveillance systems. We conducted an inventory study to calculate TB underreporting in Germany in 2013–2017. Methods Acquisition of two pseudonymized case-based data sources (national TB notification data and antibiotic resistance surveillance data) was followed by two-source Capture-recapture (CRC) analysis, as case-based data from a third source was unavailable. Aggregated data on consumption of a key anti-TB drug (pyrazinamide [PZA]) was compared to an estimated need for PZA based on TB notification data to obtain an independent underreporting estimation. Additionally, notified TB incidence was compared to TB rate in an aggregated health insurance fund dataset. Results CRC and PZA-based approaches indicated that between 93 and 97% (CRC) and between 91 and 95% (PZA) of estimated cases were captured in the national TB notification data in the years 2013–2017. Insurance fund dataset did not indicate TB underreporting on the national level in 2017. Conclusions Our results suggest that more than 90% of estimated TB cases are captured within the German TB surveillance system, and accordingly the TB notification rate is likely a good proxy of the diagnosed TB incidence rate. An increase in underreporting and discrepancies however should be further investigated.Peer Reviewe

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13

In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case–control study (MCCS) in seven European Union (EU) Member States to measure 2012/13 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory confirmed as influenza. The season was characterised by substantial co-circulation of influenza B, A(H1N1)pdm09 and A(H3N2) viruses. Practitioners systematically selected ILI patients to swab ≤7 days of symptom onset. We compared influenza-positive by type/subtype to influenza-negative patients among those who met the EU ILI case definition. We conducted a complete case analysis using logistic regression with study as fixed effect and calculated adjusted vaccine effectiveness (AVE), controlling for potential confounders (age, sex, symptom onset week and presence of chronic conditions). We calculated AVE by type/subtype. Study sites sent 7,954 ILI/acute respiratory infection records for analysis. After applying exclusion criteria, we included 4,627 ILI patients in the analysis of VE against influenza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 cases) and 3,340 for influenza A(H3N2) (730 cases). AVE was 49.3% (95% confidence interval (CI): 32.4 to 62.0) against influenza B, 50.4% (95% CI: 28.4 to 65.6) against A(H1N1)pdm09 and 42.2% (95% CI: 14.9 to 60.7) against A(H3N2). Our results suggest an overall low to moderate AVE against influenza B, A(H1N1)pdm09 and A(H3N2), between 42 and 50%. In this season with many co-circulating viruses, the high sample size enabled stratified AVE by type/subtype. The low estimates indicate seasonal influenza vaccines should be improved to achieve acceptable protection levels

Vollständigkeit der Tuberkulose-Meldungen in Deutschland in den Jahren 2013 – 2017: Ergebnisse einer Inventurstudie

Für die Evaluation der Qualität von Tuberkulose-Meldesystemen ist die Bewertung der Vollständigkeit der Meldedaten von zentraler Bedeutung, da diese die Basis für eine aussagekräftige Tuberkulose-Surveillance und daraus abgeleitete Maßnahmen sind. Wie das Epidemiologische Bulletin 11/2021 beschreibt, wurde am Robert-Koch-Institut für den Zeitraum 2013-17 eine Inventarstudie zur Schätzung der Tuberkulose-Untererfassung in Deutschland durchgeführt. Das Ergebnis: mit einer Erfassungsquote von über 90% ist die Tuberkulose-Melderate trotz eines leichten Rückgangs innerhalb des untersuchten Zeitraums ein guter Näherungswert für die tatsächliche Tuberkulose-Inzidenz

Varicella vaccination coverage of children under two years of age in Germany

Background: Since July 2004, routine varicella vaccination is recommended by the German Standing Vaccination Committee in Germany. Health Insurance Funds started to cover vaccination costs at different time points between 2004 and 2006 in the Federal States. Nationwide representative data on vaccination coverage against varicella of children under two years of age are not available. We aimed to determine varicella vaccination coverage in statutory health insured children under two years of age in twelve German Federal States using data from associations of statutory health insurance physicians (ASHIPs), in order to investigate the acceptance of the recommended routine varicella vaccination programme. Methods: We analysed data on varicella vaccination from 13 of 17 ASHIPs of the years 2004 to 2007. The study population consisted of all statutory health insured children under two years of age born in 2004 (cohort 2004) or 2005 (cohort 2005) in one of the studied regions. Vaccination coverage was determined by the number of children vaccinated under 2 years of age within the study population. Results: Varicella vaccination coverage of children under two years of age with either one dose of the monovalent varicella vaccine or two doses of the measles, mumps, rubella, and varicella vaccine increased from 34% (cohort 2004) to 51% (cohort 2005) in the studied regions (p < 0.001). More than half of the vaccinated children of cohort 2004 and two third of cohort 2005 were immunised at the recommended age 11 to 14 months. The level of vaccination coverage of cohort 2004 was significantly associated with the delay in introduction of cost coverage since the recommendation of varicella vaccination (p < 0.001). Conclusions: Our study shows increasing varicella vaccination coverage of young children, indicating a growing acceptance of the routine varicella vaccination programme by the parents and physicians. We recommend further monitoring of vaccination coverage using data from ASHIPs to investigate acceptance of the routine vaccination programmes over time

I-MOVE multicentre case–control study 2010/11 to 2014/15 : is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

Influenza vaccines are currently the best method available to prevent seasonal influenza infection. In most European countries one dose (or two doses for children) of seasonal vaccine is given from September to December to the elderly and other target groups for vaccination. In Europe, influenza seasons can last until mid-May (1), and it is expected that vaccination conveys protection on the individual for the duration of the season. In 13/15 reviewed studies on the length of vaccine-induced protection among the elderly, using anti-haemagglutination antibody titres as a proxy for seroprotection levels, seroprotection rates lasted at least >4 months after vaccination (2). However in the 2011-12 influenza season various studies in Europe reported a decrease in influenza vaccine effectiveness (VE) against A(H3N2) over time within the season (3–5). In the United States, a decrease in VE against A(H3N2) with time since vaccination was suggested in the 2007-8 influenza season (6). The observed decrease of VE over time can be explained by viral change (notably antigenic drift) occurring in the season. Drift in B viruses may be slower than in A viruses (7), and A(H3N2) viruses undergo antigenic drift more frequently than A(H1N1)pdm09 viruses (8). The decrease of VE over time can also be explained by a waning of the immunity conferred by the vaccine independently from viral changes. If vaccine-induced protection wanes more rapidly during the season, then depending on the start and duration of the influenza season, the decline of VE may cause increases in overall incidence, hospitalisations and deaths. Changes to vaccination strategies (timing and boosters) may be needed. As anti-haemagglutination antibody titres are not well defined as a correlate of protection (9,10), vaccine efficacy (as measured in trials) or vaccine effectiveness observational studies may be one way to measure vaccine-induced protection. These studies require a large sample size to model VE by time since vaccination and currently, most of the seasonal observational studies lack the precision required to provide evidence for waning immunity. In this study we pooled data across five post-pandemic seasons (2010/11-2014/15) from the I-MOVE (Influenza - Monitoring Vaccine Effectiveness) multicentre case control studies (1,3,11,12), to obtain a greater sample size to study the effects of time since vaccination on influenza type/subtype-specific VE. We measure influenza type/subtype-specific VE by time since vaccination for the overall season, but also in the early influenza phase; under the hypothesis that virological changes are fewer in the early season, but waning of the vaccine effect should be present regardless of time within the influenza phase

Bestimmung von Impfquoten und Inzidenzen impfpräventabler Erkrankungen anhand von Daten der Kassenärztlichen Vereinigungen

Hintergrund: Die Surveillance (Überwachung) von impfpräventablen Erkrankungen in Deutschland beruht im Wesentlichen auf der Meldepflicht gemäß Infektionsschutzgesetz. Eine kontinuierliche Erhebung von bundesweiten Impfquoten findet hauptsächlich im Rahmen der Schuleingangsuntersuchungen statt. Daher sind Kenntnisse über bundesweite Inzidenzen (Neuerkrankungsraten) von nicht-meldepflichtigen Erkrankungen und Impfquoten der Zielgruppen von Impfprogrammen für verschiedene Altersgruppen lückenhaft. Das Ziel der Promotionsarbeit besteht darin, zu untersuchen, inwieweit die Daten der Kassenärztlichen Vereinigungen (KVen) genutzt werden können, um repräsentativ für Deutschland Impfquoten und Inzidenzen impfpräventabler Erkrankungen zu bestimmen. Methodik. Die Kassenärztlichen Vereinigungen übermitteln im Rahmen des Projekts „KVSentinel“ pseudonymisierte Daten zu Masern, Mumps, Keuchhusten, Windpocken (Varizellen) und Herpes zoster sowie zu den von der Ständigen Impfkommission empfohlenen Standardimpfungen an das Robert Koch-Institut. Studienpopulation sind die gesetzlich krankenversicherten Personen (ca. 85,5% der Bevölkerung). Ergebnisse: Es wurde ein methodisches Konzept entwickelt, das die Qualitätssicherung der KVDaten sowie die Etablierung von geeigneten Bezugsgrößen für die Berechnung von Impfquoten und Inzidenzen umfasst. Die Analysen zu Varizellenimpfungen, Influenzaimpfungen und Maserndiagnosen zeigen, dass anhand der KV-Daten Impfquoten und Inzidenzen für jedes Alter berechnet werden können. Weiterhin erlauben die Daten die Untersuchung, ob Impfungen zeitgerecht erfolgen, ob sich Personen regelmäßig impfen lassen und ob das Meldesystem die Zahl der Erkrankungen unterschätzt. Schlussfolgerungen: Die Daten der KVen erlauben Aussagen über die Umsetzung von Impfempfehlungen und schließen damit eine Wissenslücke. Die in der vorliegenden Promotionsarbeit etablierte Methodik zur Nutzung der Daten ist die Grundlage für ein kontinuierliches Monitoring von bundesweiten altersspezifischen Impfquoten und Inzidenzen impfpräventabler Erkrankungen

Treatment outcome in children with nontuberculous mycobacterial lymphadenitis: A retrospective follow-up study

Introduction: Information on the long-term treatment outcome following nontuberculous mycobacterial (NTM) lymphadenitis is very limited. We performed a study to (a) compare cure rates following different initial treatment courses, (b) describe subsequent treatment courses and their outcomes, and (c) determine the occurrence of late sequelae in immunocompetent children with NTM lymphadenitis. Materials and Methods: In 2011, we conducted a retrospective follow-up study in 71 parents whose children had been hospitalized with NTM disease 2002–2005. A telephone survey was performed using a standardized questionnaire to collect information on the therapeutic management and treatment outcome. Results: Of 61 children with NTM lymphadenitis, 33 (54%) children were cured after the initial treatment. We found no significant difference in cure rates following surgical intervention only (45%, 13/29 children) and a combination of surgical intervention and chemotherapy (61%, 19/31 children). In 7 out of 11 children, the cure rate following complete lymph node excision was 64%. Subsequent courses of treatment including repeated surgical intervention, combination therapy, chemotherapy only, and wait-and-see strategy in children where initial therapy failed resulted in the cure of all 61 children. In four children (7%), recurrences were observed up to 5 years later. Conclusions: Our study showed that recurrent NTM lymphadenitis might be observed several years after initial resolution of disease. The cure rate following complete lymph node excision was lower than reported in other studies. Subsequent treatment courses were necessary in half of the children. Physicians and parents need to be aware that NTM lymphadenitis in children requires careful choice of intervention and active follow-up

Überblick und Bewertung der verfügbaren Datenquellen zur Inzidenz impfpräventabler Krankheiten, zum Durchimpfungsgrad und zum Immunstatus in Deutschland

Die Surveillance von impfpräventablen Erkrankungen und durchgeführten Impfungen ist notwendig, um entsprechend den Impfempfehlungen und den verfolgten gesundheitspolitischen Zielen epidemiologische Daten zu liefern. Die verfügbaren Datenquellen für die Erfassung von Neuerkrankungen an impfpräventablen Krankheiten, zum Durchimpfungsgrad und zum Immunstatus der Bevölkerung sind lückenhaft und liefern kein vollständiges Bild der epidemiologischen Situation. Für die Mehrheit der impfpräventablen Krankheiten gibt es durch die Meldepflicht und zusätzliche Sentinels bundesweite Daten über ihr Vorkommen. Einige, für die Regelimpfungen empfohlen sind, stehen jedoch nicht unter einer Surveillance. Die Erhebung von Daten zu durchgeführten Impfungen erfolgt in Deutschland dezentral und regional. Bundesweit kontinuierlich erhobene Daten zu Impfquoten liegen ausschließlich für Schulanfänger vor. Die Analyse von Versorgungsdaten, wie zum Beispiel von Daten der Krankenkassen oder Kassenärztlichen Vereinigungen, kann eine Möglichkeit sein, diese Datenlücken zu schließen.The surveillance of vaccine preventable diseases and vaccination coverage is necessary in order to deliver epidemiological data with respect to national vaccination recommendations and control targets. The data available on the incidence of vaccine preventable diseases, vaccination coverage, and immune status of the population are fragmentary and do not allow the epidemiological situation to be fully assessed. Although the majority of vaccine preventable diseases are under surveillance nationwide (by statutory reporting or sentinel surveillance), data are not available for some diseases. In addition, data on vaccination coverage are not collected centrally. Nationwide data on vaccination coverage are only available for children at school entry. Use of secondary data such as data from health insurance companies or associations of statutory health insurance physicians provides an opportunity to close gaps in knowledge and to improve the surveillance of vaccine preventable diseases